Cytomx Therapeutics Aktie
WKN: A14158 ISIN: US23284F1057
aktueller Kurs:
6,09
Veränderung:
0,11
Veränderung in %:
1,84 %
weitere Analysen einblenden

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX

Dienstag, 07.07.20 22:55
Monitoransicht mit Chart.
Bildquelle: pixabay


PR Newswire





NEW YORK, July 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 13, 2020, inclusive (the "Class Period"), of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for CytomX investors under the federal securities laws.



To join the CytomX class action, go to http://www.rosenlegal.com/cases-register-1860.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (2) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (3) as a result, CytomX's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1860.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com   

www.rosenlegal.com





Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-reminds-cytomx-therapeutics-inc-investors-of-important-deadline-in-securities-class-action--ctmx-301089547.html

SOURCE Rosen Law Firm, P.A.





Quelle: PR Newswire




Hier geht's zur Aktien-Startseite

News und Analysen

ROSEN, A LONGSTANDING AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - CTMX

PR NewswireNEW YORK, July 10, 2020NEW YORK, July 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, ...weiterlesen

Seite: 1 | 2 | 3 | ►

Volltextsuche

Im Fokus

Aktueller Chart
  • Corona-Krise beflügelt Amazon!
  • Quartalsgewinn verdoppelt!
  • Jetzt kostenlosen Spezialreport sichern!

Nachrichtensuche

Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr